Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Laquinimod 0.6 mg versus placebo in relapsing-remitting multiple sclerosis
2007-003226-19Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in relapsing-remitting multiple sclerosis (RRMS) and multiple sclerosis (MS) comparing Laquinimod 0.6 mg with Placebo (2 arms). Primary endpoint: Number of confirmed relapses during the double-blind treatment phase. Started Jul 2007; status: completed.
02
Drugs
laquinimod
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)multiple sclerosis (MS)
Beyond the preview
Go deeper on 2007-003226-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003226-19.